关键词: Hydroxymethylglutaryl-CoA reductase inhibitors meta-analysis pneumonia statins stroke stroke-associated pneumonia systematic review.

Mesh : Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage adverse effects therapeutic use Pneumonia / epidemiology prevention & control Stroke / epidemiology prevention & control Risk Factors

来  源:   DOI:10.2174/0127724328258172230926070748

Abstract:
This research aimed to examine the relationship between the intake of statins and the risk of post-stroke pneumonia in a systematic review and meta-analysis study.
An extensive search of published articles on March 21st, 2023, was done in several databases, like Web of Science (ISI), PubMed, Cochrane Library, Embase, Scopus, and Google Scholar. The Newcastle Ottawa Scale (NOS) checklist was employed to evaluate the quality of observational studies. Statistical tests (Chi-square test and I2) and graphical techniques (Forest plot) were used to determine whether heterogeneity existed in the meta-analysis studies. Funnel plots and Begg and Egger\'s tests were used to assess the publication bias.
Seven studies (5 cohort and 2 case-control studies) were retrieved to examine the association between statins and post-stroke pneumonia. The sample size of the studies compiled in the meta- analysis was obtained to be 68,966 participants. Meta-analysis demonstrated that the overall odds of post-stroke pneumonia in the statin group was equal to 0.87 (95% CI: 0.67 - 1.13; p-value 0.458). Subgroup analysis indicated that the odds of post-stroke pneumonia in the statin group was equal to 0.93 (95% CI: 0.73-1.18; p-value = 0.558) in the cohort studies, and equal to 0.92 (95% CI: 0.37-2.26; p-value = 0.857) in the case-control studies. The examination of the association between the intake of statins and post-stroke pneumonia showed no evidence of publication bias (Begg\'s test, p-value = 0.368; Eggers test, p-value = 0.282).
In this study, no relationship has been observed between receiving statins and the risk of post-stroke pneumonia.
摘要:
目的:本研究旨在通过系统评价和荟萃分析研究,探讨他汀类药物摄入与卒中后肺炎风险之间的关系。
方法:对3月21日发表的文章进行了广泛的搜索,2023年,在几个数据库中完成,像WebofScience(ISI)一样,PubMed,科克伦图书馆,Embase,Scopus,谷歌学者。采用纽卡斯尔渥太华量表(NOS)检查表评估观察性研究的质量。使用统计检验(卡方检验和I2)和图形技术(森林图)来确定荟萃分析研究中是否存在异质性。漏斗图和Begg和Egger的测试用于评估发表偏倚。
结果:检索了7项研究(5项队列研究和2项病例对照研究)以检查他汀类药物与卒中后肺炎之间的关联。荟萃分析中汇编的研究样本量为68,966名参与者。Meta分析显示,他汀类药物组发生卒中后肺炎的总几率为0.87(95%CI:0.67-1.13;p值0.458)。亚组分析表明,在队列研究中,他汀类药物组发生卒中后肺炎的几率等于0.93(95%CI:0.73-1.18;p值=0.558)。在病例对照研究中等于0.92(95%CI:0.37-2.26;p值=0.857)。对他汀类药物摄入量与卒中后肺炎之间的关联的检查未显示发表偏倚的证据(Begg\s检验,p值=0.368;Eggers试验,p值=0.282)。
结论:在这项研究中,没有观察到接受他汀类药物与卒中后肺炎风险之间的关系.
公众号